In an initial study, Sornjaithe and colleagues showed that hepcidin RNA expression was more pronounced in CRC samples than in matched normal colonic samples, and the treatment of the CRC cell line HT29 with hepcidin increased cell survival. The gene discussed is HAMP; the disease is colorectal carcinoma.